Evidence map›Paper›PMID 33919763›Full record

ArticleCancers2021

Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13-

Gareth J Veal, Deborah A Tweddle, Johannes Visser, Julie Errington, Helen Buck, Josephine Marange, Jon Moss, Shiju Joseph, Hussain Mulla

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Gareth J VealNewcastle University Centre for Cancer, Translational & Clinical Research Institute Newcastle University, Newcastle upon Tyne NE2 4HH, UK.ORCID 0000-0002-1897-8678
Deborah A TweddleNewcastle University Centre for Cancer, Translational & Clinical Research Institute Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Johannes VisserCambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Julie ErringtonNewcastle University Centre for Cancer, Translational & Clinical Research Institute Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Helen BuckClinPsy Limited, St. Albans, Hertfordshire AL3 5HN, UK.
Josephine MarangeNova Laboratories Limited, Leicester LE18 4YL, UK.
Jon MossBAST Inc Limited, Loughborough Innovation Centre, Loughborough LE11 3AQ, UK.
Shiju JosephBAST Inc Limited, Loughborough Innovation Centre, Loughborough LE11 3AQ, UK.
Hussain MullaNova Laboratories Limited, Leicester LE18 4YL, UK.
Loughborough University · GBNewcastle University · GBCambridge University Hospitals NHS Foundation Trust · GBGreat North Children's Hospital · GB

Funding

Department of Health England HICF R7-393Wellcome Trust HICF R7-393
6 · The paper itself

Abstract

(1) Background: 13-

Indexed as

13-CRAliquidneuroblastomapharmacokinetics

Identifiers

PMID33919763
PMCPMC8070696
OpenAlexW3153884279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.